Minimally Invasive Biopsy Technologies Market Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2027
Research Reports
Jan 20, 2021
Market Size – USD 3,110.0 Million in 2019, Market Growth – CAGR of 9.3%, Market Trends –High demand in the consumer genomics sector
The market is expected to be driven due to a higher proliferation of the minimally invasive surgical procedures in biopsy testing and an extensive rise in the rate of breast and lung cancers globally. Around 66% of the total initial breast biopsies performed in North America are minimally invasive breast biopsies (MIBB).
Considerable numbers of the overall open excisional biopsy have been replaced by the minimally invasive biopsy technology in patients having the imaging-detected suspicious or the indeterminate breast lesions. With minimally invasive surgeries in the biopsy, higher precisions can be accumulated, which in turn helps in reducing the psychological burden that affects the patients and also helps reduce the overall cost by a significant margin.
The extensive proliferation of the minimally invasive surgical technologies and extensive rise in the requirement of biopsy tests to diagnose cancerous cells and identifying infectious, autoimmune disorders and inflammatory cases. Early detection of the cancers and higher precision compared to incisional and excisional biopsies have been the constant driving factors for this market.
Browse the full report description @ https://www.emergenresearch.com/industry-report/minimally-invasive-biopsy-technologies-market
The ambulatory surgery centers have a more convenient outpatient procedure alternative to the hospital-based inpatient systems, maintaining a strong track record of quality care. Ambulatory surgery centers, incorporating all the required and modern MIB technologies, are expected to grow fastest amongst the end-use verticals throughout the forecast period.
The therapeutic application is further segmented into Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Blood Cancer, and Non-oncology Application. Minimally invasive breast biopsy (MIBB) has been highly recommended for the pre breast cancer diagnosis and checkup globally. The MIBB is expected to grow higher during the projected period as the number of breast cancer increases.
The Asia Pacific region, due to its immense rise in the breast & lung cancers & rising usage of the MIB technologies, is expected to accelerate with the fastest growth rate of 20.1% during the projected period 2020 to 2027.
Regional Scope- North America; Europe; Asia Pacific; Central & South America; MEA
For More Details Get FREE Sample Pages of this Research Report@ https://www.emergenresearch.com/request-sample-form/75
Key players in the market include Chronix Biomedical, Biocept, Inc., F. Hoffmann-La Roche Ltd, Mauna Kea Technologies, Veracyte, Inc., Thermo Fisher Scientific, NeoGenomics Laboratories, Inc., Abcodia Ltd., Adaptive Biotechnologies, and Owlstone Medical Ltd., among others.
Technology Outlook (Revenue: USD Billion; 2017-2027)
Liquid Biopsy
Optical Biopsy
Brush Biopsy
Pigmented Lesion Assays
Breath Biopsy
Brush Biopsy
Others
Therapeutic Application Outlook (Revenue: USD Billion; 2017-2027)
Lung Cancer
Breast Cancer
Prostate Cancer
Colorectal Cancer
Blood Cancer
Non-oncology Applications
End-Use Verticals Outlook (Revenue: USD Billion; 2017-2027)
Hospitals & Clinics
Ambulatory Surgical Centers
Cancer Research Institutes
Others
Helping you establish a strong foothold in the industry
The Minimally Invasive Biopsy Technologies report highlights set of information related to pricing and the category of customers who are more than willing to pay for certain products and services. The information on opportunities as well as product features, determine which offerings or benefits command sale and identify the communications channels used by the market leaders to create premium positioning strategies as well as attract broadest share.
Browse the full report description @ https://www.emergenresearch.com/industry-report/minimally-invasive-biopsy-technologies-market
The research provides answers to the following key questions:
What is the estimated size of the Minimally Invasive Biopsy Technologies market for the forecast period, 2020 – 2027? What will be the growth rate of the industry during the estimated period?
What are the prominent driving forces likely to impact the progress of the industry across different regions?
Who are the major market players occupying a strong foothold in the Minimally Invasive Biopsy Technologies market? What are the winning strategies adopted by them to stay ahead in the competition?
What are the potential opportunities for the Minimally Invasive Biopsy Technologies market for the forecast period, 2020 – 2027?
What are the key trends expected to shape the development of the industry over the coming years?
What are the key restraints and challenges likely to hinder the growth of the Minimally Invasive Biopsy Technologies market worldwide?
Thank you for reading our report. For further information or queries about the report or customization options, please get in touch with us. We will ensure your report is tailored according to your requirements.
Related Reports:
Virtual Diagnostics Market Size To Be Worth USD 1,512.2 Million by 2027 Growing at a CAGR of 15.0% | Emergen Research
Anti-Aging Devices Market Size To Be Worth USD 14.22 Billion by 2027 | Emergen Research
Mobile Medical Apps Market Size Worth USD 17.61 Billion by 2027 Growing at a CAGR of 22.9% | Emergen Research
Isoflavones Market Size To Be Worth USD 45.22 Billion by 2027 Growing at a CAGR of 12.9% | Emergen Research
Farm Management Software and Services Market To Be Worth USD 3,015.5 Million by 2027 | Emergen Research
Tags:
, Reportedtimes, iCN Internal Distribution, Research Newswire, English